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Blood levels of growth differentiation factor-15 (GDF-15), also known as macrophage
inhibitory cytokine-1 (MIC-1), have been associated with various pathological processes
and diseases, including cardiovascular disease and cancer. Prior studies suggest
genetic factors play a role in regulating blood MIC-1/GDF-15 concentration. In the
current study, we conducted the largest genome-wide association study (GWAS)
to date using a sample of ∼5,400 community-based Caucasian participants, to
determine the genetic variants associated with MIC-1/GDF-15 blood concentration.
Conditional and joint (COJO), gene-based association, and gene-set enrichment
analyses were also carried out to identify novel loci, genes, and pathways. Consistent
with prior results, a locus on chromosome 19, which includes nine single nucleotide
polymorphisms (SNPs) (top SNP, rs888663, p = 1.690 × 10−35), was significantly
associated with blood MIC-1/GDF-15 concentration, and explained 21.47% of its
variance. COJO analysis showed evidence for two independent signals within this locus.
Gene-based analysis confirmed the chromosome 19 locus association and in addition,
a putative locus on chromosome 1. Gene-set enrichment analyses showed that the
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“COPI-mediated anterograde transport” gene-set was associated with MIC-1/GDF15
blood concentration with marginal significance after FDR correction (p = 0.067).
In conclusion, a locus on chromosome 19 was associated with MIC-1/GDF-15
blood concentration with genome-wide significance, with evidence for a new locus
(chromosome 1). Future studies using independent cohorts are needed to confirm
the observed associations especially for the chromosomes 1 locus, and to further
investigate and identify the causal SNPs that contribute to MIC-1/GDF-15 levels.
Keywords: genome-wide association study, growth differentiation factor-15, macrophage inhibitory cytokine-1,
community-based individuals, chromosome 19
INTRODUCTION
Growth differentiation factor-15 (GDF-15), also known as
macrophage inhibitory cytokine-1 (MIC-1), is a stress response
cytokine and a divergent member of the transforming growth
factor-β (TGF-β) superfamily (Bootcov et al., 1997; Breit et al.,
2011; Tsai et al., 2016). Studies have shown that the expression of
MIC-1/GDF-15 in both humans and animals is restricted under
resting conditions but can be induced in most cells or tissues by
oxidative and nitrosative stress (Unsicker et al., 2013; Wallentin
et al., 2014). Animal studies suggest that MIC-1/GDF-15 is
anti-inflammatory (Breit et al., 2011) and neuroprotective
(Strelau et al., 2000), promotes longevity (Wang et al., 2014a)
and neurogenesis (Kim et al., 2015), and inhibits atherosclerosis
development (Johnen et al., 2012). In humans, MIC-1/GDF-15
circulates in the blood of all individuals with levels of about
200-1200 pg/ml, with the concentration increasing with age
(Wiklund et al., 2010). Higher MIC-1/GDF-15 blood levels
have been associated with a variety of diseases and conditions
including inflammation (Brown et al., 2007), cardiovascular
disease (Brown et al., 2002), various types of cancer [e.g., prostate
(Brown et al., 2009), colon (Wallin et al., 2011), melanoma (Boyle
et al., 2009), pancreas (Wang et al., 2014b)] neurodegeneration
and cognitive decline (Jiang et al., 2016), and all-cause mortality
(Wiklund et al., 2010).
Genetics plays a role in determining MIC-1/GDF-15
blood concentration as indicated by its moderate heritability
(0.38 – 0.48) estimated from family based (Ho et al., 2012) and
twin-based (Wiklund et al., 2010) samples. However, so far, there
has only been one meta-analysis of genome-wide association
studies (GWASs) of blood MIC-1/GDF-15 concentration in
community-based adults (2 cohorts, total N = 3,694; Ho et al.,
2012), in which Ho et al. (2012) identified an association with
eight SNPs located in a region on chromosome 19 that includes
the MIC-1/GDF15 locus itself. The MIC-1/GDF15 gene is located
at chromosome 19p12-13.1, and comprises two exons (309 and
891 bp in length) and one 2.9 kb intron (Unsicker et al., 2013).
To better understand the genetic factors regulating blood
concentration of MIC-1/GDF-15, we have undertaken a GWAS
using a large combined sample of over 5,400 participants. In
the only available GWAS investigating the genetic variants of
MIC-1/GDF15 blood concentration in population-based samples
(Ho et al., 2012), the authors conducted a GWAS using two
samples that were also included in the current study, the
Framingham Offspring Study (N = 2796) and the PIVUS
(Prospective Investigation of the Vasculature in Uppsala Seniors,
N = 898). In addition to these two cohorts, the current study
included two additional samples, NSPHS (The Northern Sweden
Population Health Study, N = 939) and the Sydney MAS (Sydney
Memory and Aging Study, N = 807). Conditional and joint
(COJO), gene-based, and gene-set enrichment analyses were also
carried out aiming to uncover any new loci associated with
MIC-1/GDF-15 blood levels, and to elucidate the functional





The children and their spouses of the original Framingham Heart
Study participants, known as the Framingham Offspring Cohort
(Kannel et al., 1979), were included in the current study. From
the 3,532 eligible participants, those with missing MIC-1/GDF-15
measurements (n = 82), genotyping data (n = 254), or covariates
(n = 60), as well as individuals with heart failure (n = 38)
and left ventricular (LV) systolic dysfunction as revealed by
echocardiography (n = 302), were excluded (see Ho et al., 2012
for details). Finally, 2796 participants who had both genetic and
MIC-1/GDF-15 data were included in the current study (Table 1).
In the Framingham Offspring Cohort, diabetes mellitus (DM)
was defined as a fasting glucose concentration ≥ 126 mg/dL
(≥7.0 mmol/L) or the use of insulin or oral hypoglycemic
medications. Written informed consent was provided by all
participants, and the study was approved by the Institutional
Review Board, Boston University Medical Center. All analyses
described in the current study were conducted in accordance with
the approved guidelines and regulations.
Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) Study
PIVUS is a randomly recruited community-based cohort (mean
age, 70 years; N = 1,016) living in Uppsala, Sweden (Lind
et al., 2009). Participants without genotyping data (N = 67),
MIC-1/GDF-15 measurement (N = 4) or covariates (N = 14),
and those with prevalent heart failure (n = 32) and LV systolic
dysfunction (N = 1), were excluded from the current study,
leaving 898 participants for the GWAS analyses (Table 1). DM
was defined as a self-reported history of diabetes or a fasting
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TABLE 1 | Sample characteristics.
Framingham Offspring Cohort PIVUS NSPHS Sydney MAS
Sample sizea (Model 1/Model 2) 2796/2791 898/898 939/939 807/807
Age (years; mean ± SD, range) 59 ± 10, 30–79 70 ± 0.2, 69–72 50.4 ± 20.0, 14–94 78 ± 4.7, 70–91
%Female 56.0 50.7 47.0 53.0
Systolic blood pressure (mm Hg; mean ± SD) 128.32 ± 18.68 149.55 ± 22.51 125.14 ± 18.15 146.08 ± 22.03
Use of antihypertensives (%) 25.7 29.5 5.74 49.0
Diabetes mellitus (%) 9.9 10.5 1.2 14.5
Current smoking (%) 15.6 12.0 14.46 13.9
BMI (kg/m2) 27.4 ± 5.0 27.0 ± 4.5 26.7 ± 4.8 27.1 ± 4.5
MIC-1/GDF15 Overall 1165 ± 625 1212 ± 410 3.64 ± 1.15b 1295.68 ± 661.90
blood concentration (ng/L) Male 1180 ± 637 (n = 1316) 1257 ± 421 (n = 437) 3.62 ± 0.97 (n = 498)b 1431.55 ± 771.16 (n = 416)
Female 1153 ± 615 (n = 1675) 1162 ± 390 (n = 450) 3.67 ± 1.42 (n = 441)b 1175.93 ± 520.01 (n = 472)
aNumber of GWAS participants. bNSPHS – Real-time polymerase chain reaction (PCR) results were used to measure MIC-1/GDF15 blood concentration.
blood glucose ≥ 112 mg/dL (6.22 mmol/L). All participants
provided written informed consent, and the study was approved
by the University of Uppsala Ethics Committee. All analyses
were undertaken in accordance with the approved guidelines and
regulations.
The Northern Sweden Population Health Study
(NSPHS)
NSPHS is another Swedish community-based cohort with
randomly recruited participants from the parishes of Karesuando
and Soppero, County of Norrbotten (median age, 50 years;
N = 1,037; Enroth et al., 2014; Ek et al., 2016). Sixty-one
participants missing MIC-1/GDF-15 data or covariates, 26
individuals with previous heart failure, and 11 pregnant women
were excluded from the current study, leaving a total of 939
individuals being included in this study (Table 1). DM was
defined as a self-reported history of diabetes. NSPHS was
approved by the local ethics committee at the University
of Uppsala in compliance with the Declaration of Helsinki.
All participants gave their written informed consent. Parental
consent is obtained for all participants under the age of 16. All
analyses in the current study were conducted in accordance with
the approved guidelines and regulations.
Sydney Memory and Aging Study (Sydney MAS)
Sydney MAS is a community-based longitudinal study of
older adults aged 70–90 years living in Sydney, NSW,
Australia (Sachdev et al., 2010). Briefly, 1037 non-demented
community-dwelling participants were randomly recruited from
the compulsory electoral rolls of two regions in Sydney,
NSW, Australia. Serum MIC-1/GDF-15 measurement was
undertaken in 888 individuals. After excluding individuals
without genotyping data (n = 53) and covariates (n = 28),
807 were included in the GWAS analyses (Table 1). DM
in Sydney MAS was defined as a self-reported history of
diabetes, current usage of diabetes medication or a fasting
blood glucose ≥ 126 mg/dL (7.0 mmol/L). Sydney MAS
was approved by the Human Research Ethics Committees of
the University of New South Wales and the South Eastern
Sydney Local Health District. All participants gave written
informed consent. All analyses in the current study were
performed in accordance with the approved guidelines and
regulations.
MIC-1/GDF-15 Measurement
Framingham Offspring Cohort blood samples were collected
after an overnight fast, and centrifuged immediately.
Citrate-treated plasma samples were then stored at −80◦C
until MIC-1/GDF-15 measurement, which was undertaken using
an electrochemiluminescence MIC-1/GDF-15 immunoassay on
a Cobas e 411 analyzer (Roche Diagnostics). Further details of
the assay have been described previously (Kempf et al., 2007; Ho
et al., 2012).
In PIVUS, MIC-1/GDF-15 levels were determined with an
immunoradiometric assay from stored frozen (−70◦C), fasting
EDTA-plasma samples. Details of MIC-1/GDF15 measurements
in PIVUS have been reported previously (Kempf et al., 2007;
Maggio et al., 2014).
In NSPHS, MIC-1/GDF-15 concentrations were quantified in
non-fasting plasma samples as part of the Proseek R© Multiplex
immunoassay ONC1v1 panel as described previously (Assarsson
et al., 2014; Enroth et al., 2014). NSPHS MIC-1/GDF-15
measurements were not converted into actual concentrations
due to the assay method but should be comparable to the
MIC-1/GDF-15 levels used in other cohorts after inverse normal
transformation.
In Sydney MAS, the MIC-1/GDF-15 serum levels were
determined in fasting serum samples using an enzyme-linked
immunosorbent assay (ELISA), which is established using the
mouse monoclonal antibody 13C4H3 for antigen capture, and the
sheep polyclonal antibody 233B3-P for detection as described in
detail previously (Jiang et al., 2015).
Genotyping and Imputation
Genotyping of Framingham Offspring Cohort was performed
using the Affymetrix 500K mapping and the 50K gene-focused
MIP arrays (CA, United States) (Ho et al., 2012). Imputation of
genotypes to the HapMap2 reference panel (2.5 million SNPs,
CEU population, release 22, build 36) was implemented in
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MACH1 (version 1.0.15, Li and Abecasis, 2006) as described in
Ho et al. (2012). Imputed/assayed genotypes were produced for
2,540,223 HapMap2 SNPs.
In PIVUS, genome-wide genotyping was undertaken using the
Illumina OmniExpress Bead array and the CardioMetabochip
(San Diego, CA, USA). Imputation of genotypes to the same
HapMap2 reference panel as Framingham was undertaken using
IMPUTE (version 2.2.2), resulting in 2,592,180 imputed/assayed
SNPs. Further details can be found in (Ho et al., 2012).
DNA samples from NSPHS were genotyped on Illumina
Infinium HumanHap300v2 or HumanCNV370v1 SNP bead
microarrays. Imputation was performed using IMPUTE (version
2.2.2) based on the 1000 Genome Project Phase 3 reference panel,
resulting in 8.89 million assayed/imputed SNPs.
In Sydney MAS, genotyping was undertaken using the
Affymetrix Genome-wide Human SNP Array 6.0 at the
Ramaciotti Centre, UNSW Australia. Imputation was
implemented in MACH (Li et al., 2009, 2010) using the HapMap2
reference data (release 22, build 36). Detailed genotyping and
imputation procedures have been described previously (Mather
et al., 2016). A total of 2,543,888 SNPs were assayed/imputed.
GWAS, Replication, and Meta-Analysis
A normal distribution of MIC-1/GDF-15 blood concentration
was achieved through applying an inverse normal transformation
to all cohorts. SNPs with imputation quality > 0.8 and minor
allele frequency (MAF) > 0.05 (HapMap 2) were used for
the current study. GWAS and meta-analyses were carried out
using two Models. In Model 1, age, sex, systolic blood pressure,
antihypertensive medication use, diabetes mellitus, and smoking
status were used as covariates. NSPHS also included a dummy
variable indicating the year of data collection (2006 or 2009). For
Model 2, body mass index (BMI) was also included in addition
to Model 1 covariates, because BMI has been associated with
MIC-1/GDF-15 concentrations in prior studies (Tsai et al., 2015).
For the GWAS, Framingham used a linear mixed model
to accommodate the relatedness among the participants
as implemented in the R program package, genome-wide
association analyses with family (GWAF). PIVUS, NSPHS and
Sydney MAS applied a linear model for the GWAS analyses
using SNPTEST (Marchini et al., 2007), ProbABEL (Aulchenko
et al., 2010), and mach2qtl (Li et al., 2010) software respectively.
PIVUS adjusted for 2 principal components (PCs) to account for
population stratification. Population stratification in NSPHS was
adjusted for using the kinship matrix. Sydney MAS PCs were not
used as covariates as ethnic outliers had already been removed
and there was no evidence of population stratification based on
multidimensional scaling (MDS) plots (Mather et al., 2016).
The meta-analyses were undertaken in the discovery cohorts
(Framingham Offspring Cohort, PIVUS, and NSPHS) using the
fixed effects inverse variance weighted method implemented
in the package METAL, based on the GWAS SNPs summary
statistics beta and its standard errors. Sydney MAS was used
as a replication cohort because MIC-1/GDF-15 was measured
in serum (rather than plasma), and also the Sydney MAS
1http://csg.sph.umich.edu/abecasis/mach/index.html
participants were older than the other three cohorts. All results
are reported using the 1000 Genome reference panel (NCBI
Build 37) coordinates for consistency. The GWAS summary
statistics are available at https://www.cheba.unsw.edu.au/group/
genetics-genomics, or from the corresponding author, Karen A.
Mather, on request.
Functional Annotation
The functional significance of the top SNPs from the
meta-analysis were explored in silico using public
databases/browsers, including GTEx2, RegulomeDB (Boyle
et al., 2012), and SNiPA3. The search in RegulomeDB was
performed using a 20 k base pair window around the top SNPs.
GeneCards4 was used to reveal gene functions. In addition, any
previously associated phenotypes of the top SNPs were identified
using the GWAS Central database5.
Conditional and Joint (COJO) Analysis
We performed two types of conditional analyses to explore
secondary signals from other loci. First, we conditioned the
genome-wide discovery meta-analysis results with the top
SNP from the meta-analysis using the program, Genome-wide
Complex Trait Analysis (GCTA) (Yang et al., 2011).
Further, to test the joint association of multiple SNPs around
the top hits, we used the COJO analysis implemented in GCTA.
The COJO analysis uses a reference panel to calculate linkage
disequilibrium (LD) between SNPs. As we do not have access
to the genotyping data of the discovery cohorts, we used the
1000 Genome phase 3 European reference panel for this analysis.
We performed COJO for each chromosome separately with
a liberal GWAS threshold of p0 = 10−5. The COJO analysis
starts with the top SNP (smallest p < p0) in the meta-analysis.
For the next iteration, p-values of the rest of the SNPs are
calculated by conditioning on the top selected SNPs. To avoid
multicollinearity, SNPs in high LD (r2 > 0.9) with the selected
top SNP are not considered for COJO analyses. After that,
a new top SNP is selected based on the conditional analysis
of all the SNPs already selected, and then a joint association
of all the selected SNPs is finished. The iteration continues
until no new SNP can be selected or removed from the joint
analysis.
Gene-Based Association Analysis
Gene-based association analysis was conducted in a
hypothesis-free manner through applying the Versatile Gene-
based Association Study (VEGAS) algorithm (Liu et al., 2010) to
the genome-wide meta-analysis results of the discovery cohorts.
SNPs within ± 10 kb of a gene were used in this analysis, and
the results of the p-values within the corresponding gene were
calculated using (i) the top 10% or (ii) all SNPs. We used 1000
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Gene-Set Enrichment Analysis
The genome-wide meta-analysis results from the discovery
samples were tested for enrichment of genetic associations
with pre-specified functionally related gene-sets and biological
processes using the program, meta-analysis gene-set enrichment
of variant associations (MAGENTA, Ver. 2.4, Segre et al., 2010).
The MAGENTA analysis was run in a hypothesis-free way, and
6 public databases were combined and included in the analysis,
namely GO Terms, the protein analysis through evolutionary
relationships (PANTHER), Ingenuity, the Kyoto Encyclopaedia
of Genes and Genomes (KEGG), Biocarta, and Reactome. SNPs
that are located 100 KB upstream of the start and 100 KB
downstream of the end of a gene were considered to contribute
to the effect of the gene.
Generally, associations with p-values less than 5 × 10−8
were regarded as genome-wide significant. A liberal threshold
of ≤1 × 10−5 was applied to discover any suggestive SNPs. For
the replication GWAS in Sydney MAS, a p-value less than 0.05
was considered as statistical significant. In gene-set enrichment
analyses, after false discovery rate (FDR) correction, associations
with p < 0.05 were regarded as statistical significant, and those




The sample characteristics are summarized in Table 1.
The discovery sample was comprised of 4,633 individuals
(Framingham Offspring Cohort, PIVUS, NSPHS), and 807
participants from Sydney MAS were used for replication.
NSPHS had the widest age span (14–94 years) of the four
cohorts, whereas Sydney MAS participants were the most elderly
(mean age, 78 years). In all participating cohorts, there were
approximately equal numbers of females and males (range
47.0–56.0%).
GWAS Meta-Analysis in Discovery
Samples
GWAS were undertaken in each participating cohort, and
the Manhattan and QQ plots are shown in Supplementary
Figures 1–4.
The results of the GWAS meta-analysis in the discovery
cohorts (Model 1) showed a clear genome-wide significant
peak on chromosome 19 (Figure 1A). The QQ plot for the
meta-analysis did not show any inflation of the test statistics
(lambda gc = 1.004, Figure 1B). There were nine genome-wide
significant SNPs on chromosome 19 (Table 2 and Supplementary
Table 1). Of the nine SNPs, three were located in the 3′
untranslated region (UTR) of the pyroglutamyl-peptidase I
(PGPEP1) gene, three in the downstream region of the PGPEP1
gene, one in the intron of the MIC-1/GDF15 gene, one in
the 3′ UTR of the MIC-1/GDF15 gene, and one in the
downstream of the MIC-1/GDF15 gene. A regional association
plot around the MIC-1/GDF15 gene, showing the top SNP,
rs888663, and the genes in this region is shown in Figure 2.
The top three SNPs (rs888663, rs3746181, rs1363120) are in
high linkage disequilibrium (LD; r2 > 0.95, Supplementary
Figure 5). Results were similar for the meta-analysis using
Model 2 (see Supplementary Table 2), and hence all following
analyses are based on Model 1. The Manhattan and QQ plots
of the meta-analysis using Model 2 are shown in Supplementary
Figures 6, 7, respectively.
Replication in Sydney MAS
Among the nine genome-wide significant SNPs in the discovery
meta-analysis, only three replicated with significance (p < 0.05)
in the replication cohort (i.e., Sydney MAS), namely rs1054564,
rs1227731, and rs3195944 (Table 2 and Supplementary
Table 3).
In a meta-analysis of all cohorts (i.e., both discovery and
replication samples), eight of the nine top SNPs remained
genome-wide significant in Model 1 (Supplementary Table 4).
Functional Annotation
Using public databases (see Materials and Methods), seven
out of the nine significant SNPs were identified as expression
quantitative loci (eQTLs) as they were associated with gene
expression in the chromosome 19 locus region in blood, B-cells,
monocyte, adipocyte, and esophagus mucosa (see Table 3 for the
full list of associated genes).
Analysis of the top SNPs using RegulomeDB is summarized in
Supplementary Table 5. Two SNPs, rs1054564 and rs16982345,
are likely to affect protein binding (i.e., high degree evidence
of regulatory function) and expression of a gene target
(i.e., 1f category). The SNP rs3746181 may also affect binding
(2b category). It is noteworthy that rs1054564 is located in the
3′ UTR of the MIC-1/GDF15 gene and the 5′ UTR of the Leucine
Rich Repeat Containing 25 (LRRC25) genes, suggesting that this
variant may be a functional SNP. The SNP rs3746181 is located
in the binding motif for transcription factor PU.1.
Conditional and Joint (COJO) Analysis
After conditioning on the top SNP of the meta-analysis
(rs888663), the SNPs, rs7226, rs12459566, rs4808793, rs8101804,
rs12459782, rs1059519, rs1059369, rs1804826, rs6512265, and
rs1043063, reached genome-wide significance (Supplementary
Table 6). The LD between these SNPs is shown in Supplementary
Figure 5. Among these SNPs, rs12459566, rs4808793, rs8101804,
rs12459782, rs1059519, and rs6512265 are in high LD (r2 > 0.97).
Another group of SNPs with high LD includes rs7226, rs1059369,
and rs1804826 (r2 > 0.86). However, these SNPs are all within
or near the block containing the significant SNPs from the
genome-wide meta-analysis.
Supplementary Table 7 shows the results from the COJO
analysis. Using a liberal p-value threshold of 1 × 10−5, the
COJO analysis did not identify any additional significant hits.
However, the region of association in chromosome 19 had two
independent signals, rs888663 and rs6512265 (r2 = 0.48) reaching
genome-wide significance (p < 5 × 10−8), explaining 2.98% of
the variance in MIC-1/GDF-15 blood concentration. The SNP
rs6512265 is located in the exon (2/2) of the LRRC25 gene
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FIGURE 1 | (A) Manhattan and (B) QQ plot for the discovery meta-analysis (Model 1).
and is an eQTL of the PGPEP1 gene in whole blood, and the
solute carrier family 25, member 42 (SLC25A42) gene in lung
tissue.
Gene-Based Association Analysis
Using a p-value cut-off of 1 × 10−5, gene-based association
analysis showed that four genes on chromosome 19
[MIC-1/GDF15, LRRC25, microRNA 3189 (MIR3189),
PGPEP1] and three genes on chromosome 1 [Beta-1,3-
Galactosyltransferase 6 (B3GALT6), Stromal Cell Derived Factor
4 (SDF4), TNF Receptor Superfamily Member 4 (TNFRSF4)] were
associated with MIC-1/GDF-15 blood concentration (Table 4).
The SNPs, rs1054564 and rs888663, are primarily driving the
observed associations between the genes on chromosome 19 and
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TABLE 2 | Genome-wide significant GWAS meta-analysis and replication results (Model 1).















19 rs888663 18484922 PGPEP1 Downstream T/G 1.690E-35 0.191 2.644E-35
19 rs3746181 18477017 PGPEP1 3′ UTR G/A 2.783E-35 0.425 1.839E-34
19 rs1363120 18482304 PGPEP1 Downstream G/C 6.626E-35 0.389 3.737E-34
19 rs749451 18479647 PGPEP1 3′ UTR C/T 2.105E-31 0.154 2.539E-31
19 rs1054564 18499815 GDF15 3′ UTR G/C 6.242E-31 0.001 3.448E-33
19 rs1227731 18497903 GDF15 Intronic G/A 6.277E-31 0.001 3.369E-33
19 rs3195944 18476711 PGPEP1 3′ UTR A/G 2.143E-27 1.736E-04 2.388E-30
19 rs17725099 18482358 PGPEP1 Downstream G/A 5.350E-10 0.836 4.130E-08
19 rs16982345 18500722 GDF15 Downstream G/A 2.415E-09 0.915 2.750E-07
aMinor allele is the coded allele. Discovery p-values are from the GWAS meta-analysis of Framingham Offspring Cohort, PIVUS, and NSPHS. Replication p-values are
from Sydney MAS. All cohorts combined meta-analysis p-values are from the meta-analysis combining discovery and replication analyses. p-values < 5 × 10−8 are in
bold.
MIC-1/GDF-15 blood concentration, whereas the associations
between chromosome 1 genes and MIC-1/GDF-15 blood
concentration are mainly due to the signal from rs3813199,
which is an eQTL for B3GALT6 and TNFRSF18 in blood, and
likely to affect binding of transcription factors GATA1, POLR2A,
Nuclear Factor of Activated T-Cells 1 (NFATC1), Signal
Transducer and Activator of Transcription 5A (STAT5A), and
SUZ12 Polycomb Repressive Complex 2 Subunit (SUZ12)
proteins (RegulomeDB 1f category).
Enrichment Analyses
Hypothesis-free MAGENTA analyses were performed to
investigate gene-sets enriched among the variants with the
lowest p-values (Supplementary Table 8). The “COPI-mediated
FIGURE 2 | Regional association plot of 100 kb window around the MIC-1/GDF15 gene. Different colors represent the strength of the LD of each SNP with the most
significant SNP rs888663.
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TABLE 3 | Gene expression influenced by the top SNPs (eQTLs).
rsSNP ID Associated gene Tissue p-value Source
rs888663 ELL Blood 1.7E-5 SNIPA (Westra et al., 2013)
TMEM59L B-cell 3.2E-4 SNIPA (Fairfax et al., 2012)
SUGP2 Monocyte 6.1E-4 SNIPA (Fairfax et al., 2012)
rs3746181 ELL Blood 4.6E-5 SNIPA (Westra et al., 2013)
TMEM59L B-cell 3.2E-4 SNIPA (Fairfax et al., 2012)
rs1363120 ELL Blood 3.5E-5 SNIPA (Westra et al., 2013)
rs1054564 PGPEP1 Adipose - Subcutaneous 4.0E-5 GTEx
LSM4 Adipocyte 1.1E-6 SNIPA (Grundberg et al., 2012)
LRRC25 Monocyte 2.8E-72 SNIPA (Zeller et al., 2010)
rs1227731 PGPEP1 Adipose – Subcutaneous 4.0E-5 GTEx
LSM4 Adipocyte 1.0E-6 SNIPA (Grundberg et al., 2012)
rs3195944 PGPEP1 Adipose – Subcutaneous 3.0E-5 GTEx
rs16982345 KCNN1 Esophagus – Mucosa 9.9E-6 GTEx
LRRC25 Blood 5.0E-5 SNIPA (Westra et al., 2013)
LRRC25 Monocyte 2.9E-53 SNIPA (Zeller et al., 2010)
ELL, RNA polymerase II elongation factor; TMEM59L, Transmembrane Protein 59 Like; SUGP2, SURP and G-Patch Domain Containing 2; PGPEP1, Pyroglutamyl-
Peptidase I; KCNN1, Potassium Calcium-Activated Channel Subfamily N Member 1; LRRC25, Leucine Rich Repeat Containing 25.
TABLE 4 | Gene-based association analyses.
Chromosome Gene name No. of
SNPs in
the gene
Gene position Gene-based association analysis statistics Most contributing SNP
Start Stop Test p-value Top 10% p-valuea SNP ID p-value
19 GDF15 15 18486967 18509986 133.736 <1.00E-07 <1.00E-07 rs1054564 6.24E-31
19 LRRC25 17 18491953 18518415 133.736 <1.00E-07 <1.00E-07 rs1054564 6.24E-31
19 MIR3189 15 18487371 18507444 133.736 <1.00E-07 <1.00E-07 rs1054564 6.24E-31
19 PGPEP1 25 18441407 18490763 308.261 <1.00E-07 <1.00E-07 rs888663 1.69E-35
1 B3GALT6 6 1157628 1180420 22.550 5.20E-06 4.90E-06 rs3813199 2.05E-06
1 SDF4 11 1142287 1177447 22.550 1.00E-05 N.S.2 rs3813199 2.05E-06
1 TNFRSF4 9 1136705 1159548 22.550 8.20E-06 9.50E-06 rs3813199 2.05E-06
Genes with p-value ≤ 1 × 10−5 were listed in the table, 1 × 107 iterations were conducted. ap-values for the gene-based test with the top 10% of top SNPs included.
2Not significant at level of p ≤ 1 × 10−5 (p = 1.02 × 10−5).
anterograde transport” gene-set from the REACTOME database
was the only gene-set with a marginally significant FDR-corrected
p-value of 0.067. This gene-set is associated with protein secretion
from endoplasmic reticulum (ER) to the Golgi complex.
DISCUSSION
Using data from a combined sample of community-based
individuals, we identified genetic variants associated with
MIC-1/GDF-15 blood concentration using a meta-analysis of
GWAS results. The findings replicated the prior GWAS on
MIC-1/GDF-15 levels in community-based cohorts by showing
that a locus on chromosome 19 containing the PGPEP1
and MIC-1/GDF15 genes contributes to the regulation of
MIC-1/GDF-15 blood concentration. No other genome-wide
significant loci were identified from the current study, but we
observed suggestive evidence for a locus on chromosome 1.
In addition to the PGPEP1, MIC-1/GDF15 and LRRC25 genes
identified in the previous GWAS (Ho et al., 2012), the
current study suggested variants from several other genes that
may potentially contribute to the regulation of the blood
concentration of MIC-1/GDF-15, including MIR3189 (chr 19),
B3GALT6 (chr 1), SDF4 (chr 1), and TNFRSF4 (chr 1) genes.
In the discovery sample, nine SNPs located in a region on
chromosome 19 were genome-wide significantly associated with
MIC-1/GDF-15 blood concentration. This is in line with the
previous GWAS on MIC-1/GDF-15 blood levels (Ho et al.,
2012) with a new SNP rs16982345 (9th ranked SNP) identified.
However, when examined at the individual cohort level, this
new SNP was only significant in the Framingham Offspring
Cohort. It is also noted that the genome-wide significance for
rs17725099 (8th ranked SNP) is likely to be primarily driven
by the associations in Framingham Offspring Cohort, given the
notably smaller β and greater p values in PIVUS and NSPHS.
Interestingly, on inspection of the GWAS Central catalog, many
of the top SNPs have been nominally associated with various
phenotypes, including pulmonary function, proinsulin levels,
fibrinogen, fasting insulin, inflammatory bowel disease, breast
cancer, and BMI (Supplementary Table 9). Previous studies
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have also found associations between MIC-1/GDF-15 blood
concentration and these traits (Li et al., 2000; Vila et al., 2011;
Brown et al., 2012; Rossaint et al., 2013; Mehta et al., 2014; Tiwari
et al., 2015), which may be partly driven by the SNPs identified
in the current study. However, in Sydney MAS, the top SNPs
were not associated with history of stroke, cancer, or depression.
Their associations with Framingham cardiovascular risk scores
were also not statistically significant (data not shown).
Notably, only three out of the nine SNPs were replicated
in an independent cohort (i.e., Sydney MAS) and in the
same effect direction as the discovery meta-analysis (rs1054564,
rs1227731, rs3195944). A few factors may contribute to the lack
of replication of all of the findings. The participants of the
replication cohort, Sydney MAS, are the most elderly of the four
participating cohorts, and MIC-1/GDF-15 blood concentration
has been shown to increase steadily with age (Wiklund et al.,
2010), possibly because of aging-related chronic, low-grade
inflammation (Franceschi and Campisi, 2014). This may have
weakened the contribution of genetic factors in determining
MIC-1/GDF-15 blood concentration in this aged cohort. It is
noteworthy that the three replicated SNPs are the only SNPs
that reached genome-wide significance in PIVUS, which shares
a similar age range (but still ∼8 years younger in average age)
with Sydney MAS. In addition, the fact that Sydney MAS acquired
MIC-1/GDF-15 concentration in serum, whereas the other three
cohorts used plasma, may have also introduced measurement
differences.
The majority of the top SNPs (7 out of 9) were identified as
eQTLs, but not specifically for MIC-1/GDF-15, although all of
the target genes were located in the same genomic region. Of
interest, in blood, the SNPs rs888663, rs3746181, and rs1363120,
are eQTLs of ELL, which regulates cell proliferation and survival
(Johnstone et al., 2001). This is in line with previous findings
on the role of MIC-1/GDF-15 in cell proliferation (Duong Van
Huyen et al., 2008) and neurogenesis (Kim et al., 2015). In
addition, the SNP rs16982345 is an eQTL for LRRC25 in blood,
which is involved in the innate immune response (Ng et al., 2011).
According to GTEx, both ELL and LRRC25 are highly expressed
in the blood.
Gene-based association analyses identified four chromosome
19 and three chromosome 1 genes associated with MIC-1/GDF-
15 blood levels. Of the four chromosome 19 genes, PGPEP1 is a
cytosolic cysteine peptidase that is involved in neurophysiological
processes in the synaptosomal and myelinic fractions of human
and rat brains (Larrinaga et al., 2005). LRRC25 contributes to
the detection of pathogen-associated molecular patterns during
innate immune sensing (Ng et al., 2011). Consistent with the
current findings, variation in the PGPEP1 and LRRC25 genes
has been associated with MIC-1/GDF-15 blood levels in the
previous MIC-1/GDF-15 GWAS (Ho et al., 2012). MIR3189
is a novel, p53-regulated micro RNA (miRNA) located in the
intron of MIC-1/GDF15, which is also targeted by p53. It inhibits
the expression of cell-cycle-control- and cell-survival-related
genes, as well as many p53 inhibitors leading to upregulated
MIC-1/GDF15 gene expression (Jones et al., 2015). Moreover,
in p53-deficient cells, MIR3189 overexpression also elevates
MIC-1/GDF15 gene expression. In addition to the chromosome
19 genes, gene-based association analyses also revealed that a
locus on chromosome 1 showed a suggestive association with
MIC-1/GDF-15 blood concentration, which is mainly due to
the SNP rs3813199. This variant is located in the intron of the
SDF4 gene, which encodes a stromal cell derived factor belonging
to the CREC family (Scherer et al., 1996), with involvement in
regulating calcium-dependent cell activities (Chen et al., 2016).
The SNP, rs3813199, is also an eQTL for B3GALT6, whose
protein modulates heparin sulfate, which binds to unprocessed
MIC-1/GDF-15 in the extracellular matrix (Bauskin et al.,
2005), and therefore may affect MIC-1/GDF-15 deposition and
processing in local tissues, and its blood levels. In addition,
B3GALT6 is associated with progeria, which is consistent with
the previously observed association between MIC-1/GDF-15 and
longevity (Wang et al., 2014a).
The current study suggested an association between
MIC-1/GDF-15 blood concentration and the COPI-mediated
anterograde transport pathway, which involves ER-to-Golgi
transport, and is known as the secretion pathway of cytokines
from macrophages (Murray and Stow, 2014). The current finding
therefore suggests that ER-to-Golgi pathway may potentially
play an important role in determining MIC-1/GDF-15 blood
concentration (Bootcov et al., 1997).
A high priority target for future studies attempting to identify
the causative SNP/s for MIC-1/GDF-15 levels includes examining
the SNP rs1054564 (3′ UTR [GDF15]/5′UTR [LRRC25]), which
from in silico analysis suggests it has a likely regulatory
role and is an eQTL for LRRC25. MIR3189 (chr19) is also
an interesting candidate gene, which is located within the
MIC-1/GDF-15 gene, given the evidence discussed above. The
tentative chromosome 1 locus also deserves more investigation,
with the intronic SDF4 SNP, rs3813199, an attractive candidate
as it may affect the binding of several transcription factors and
is an eQTL in blood for B3GALT6 and TNFRSF18, which have
been implicated in MIC-1/GDF-15 protein binding and immune
function respectively. The question also arises as to whether the
products of the identified genes, such as LRRC25, are involved
in the regulation of MIC-1/GDF-15 protein levels. Indeed,
LRRC25 has recently been described as a negative regulator of
the NF-κB signaling pathway that regulates gene expression,
including inflammation and immunity (Feng et al., 2017). It is
also noteworthy to mention that eQTLs for MIC-1/GDF-15 in
blood have been identified (GTEx) but were not significant in
the current study. There may be different explanations for this
discrepancy, including that other factors play important roles in
the regulation of MIC-1/GDF-15 protein blood levels such as the
protein turnover rate.
The current study has some limitations. First, MIC-1/GDF-15
measurement protocols are not identical across all participating
cohorts (e.g., different MIC-1/GDF-15 assays), which may
introduce additional variation in MIC-1/GDF-15 blood
levels. For example, plasma samples acquired from NSPHS
participants were non-fasting, which may introduce fluctuations
in MIC-1/GDF-15 measurement as it varies in a diurnal pattern
(Tsai et al., 2015), and therefore may have added heterogeneity
to the analyses. Second, the participating cohorts are of different
age ranges. Since older age is a potent risk factor for elevated
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MIC-1/GDF-15 blood levels, a comparable age range across
all participating cohorts will minimize the age effect. Third,
the definition of DM was not identical across all participating
cohorts, which may introduce biases to the results. Fourth, the
LD of the European reference panel used for COJO analyses
may not perfectly match the study samples, which may therefore
introduce potential biases to COJO analyses results. Fifth,
diseases known to elevate MIC-1/GDF-15 blood levels, such as
renal disease and rheumatoid arthritis, are not comprehensively
documented throughout all participating cohorts. Therefore,
although our community-dwelling cohorts are generally healthy,
we could not exclude the possibility that up-regulation of blood
MIC-1/GDF-15 levels due to these diseases may influence
the observed associations. Sixth, a larger sample size would
enable relatively weaker associations to be observed. Finally, the
HapMap2 reference panel does not include the most up-to-date
set of genetic variants. Future use of more up-to-date panels such
as the 1000 Genome reference panel for imputation, will facilitate
a more comprehensive set of variants to be examined.
CONCLUSION
In a GWAS of approximately 5,400 community-based
participants, we identified a locus on chromosome 19 containing
the PGPEP1 and MIC-1/GDF15 genes that was associated with
MIC-1/GDF-15 blood concentration. The findings also suggest
that a few additional genes on chromosome 19 and 1, and the
COPI-mediated anterograde transport pathway, may be involved
in regulating MIC-1/GDF-15 blood levels. This work suggests
that the regulation of blood MIC-1/GDF-15 levels is complex
with genetic variation playing a significant role. Our results
warrant further independent studies to confirm the observed
relationships, and to investigate the biological mechanisms
underlying the findings, given the negative health outcomes
linked to MIC-1/GDF-15 blood levels in humans.
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